Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 4/20 | 0.52 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | ATIC | P31939 | 2/20 | 0.46 |
| ▸ | GART | P22102 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 2/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071549 | 1.00 | UMPS (0.52) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL18118150 | 1.00 | UMPS (0.52) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL14883270 | 1.00 | UMPS (0.52) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL17809083 | 1.00 | UMPS (0.52) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL17789093 | 1.00 | UMPS (0.52) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL14946101 | 1.00 | UMPS (0.52) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL15745776 | 0.87 | UMPS (0.47) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL15249855 | 0.82 | UMPS (0.51) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL15277191 | 0.80 | UMPS (0.48) | UMPSDNPH1ATICGARTFBP1 | |
| SCHEMBL15257897 | 0.80 | UMPS (0.48) | UMPSDNPH1ATICGARTFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9814760-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140105966-A1 | MODIFIED POLYNUCLEOTIDES ENCODING HEPATITIS A VIRUS CELLULAR RECEPTOR 2 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130259924-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130252281-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244279-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | UMPS 1697/4885DNPH1 2995/4885ATIC 2703/4885 |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | AQP1, AQP3, AQP4 | UMPS 504/4885DNPH1 2715/4885ATIC 1049/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | UMPS 309/4885DNPH1 2509/4885ATIC 712/4885 |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | UMPS 1599/4885DNPH1 3597/4885ATIC 235/4885 |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | UMPS 175/4885DNPH1 1229/4885ATIC 114/4885 |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | UMPS 1052/4885DNPH1 3443/4885ATIC 1192/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | UMPS 175/4885DNPH1 1229/4885ATIC 114/4885 |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | UMPS 492/4885DNPH1 2771/4885ATIC 298/4885 |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | NSUN3, PLIN3, MCOLN3 | UMPS 2052/4885DNPH1 2646/4885ATIC 1307/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | UMPS 357/4885DNPH1 2948/4885ATIC 835/4885 |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MSH2, APAF1, MCL1 | UMPS 927/4885DNPH1 3739/4885ATIC 2177/4885 |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | UMPS 799/4885DNPH1 3073/4885ATIC 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.